Adverse events of targeted therapiesKlastersky, Jean A.Current Opinion in Oncology: July 2014 - Volume 26 - Issue 4 - p 395–402 doi: 10.1097/CCO.0000000000000096 SUPPORTIVE CARE: Edited by Jean A. Klastersky Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review There is currently an explosion in the number of so-called targeted therapies. As new indications for these agents multiply, there is also an increase of new and less new side-effects. Recent findings Given this rapidly evolving field, any literature on that topic is rapidly obsolete and needs re-evaluation. Summary Targeted therapies are associated with a wide spectrum of adverse events, which cannot always be easily separated from the complications linked to cancer, its therapy, and comorbidities. A high awareness of these events might improve the patient's quality of life and contribute to the recognition of new syndromes. Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles, Brussels, Belgium Correspondence to Jean A. Klastersky, MD, PhD, Professor and Chief of Medicine (emeritus), Institut Jules Bordet, 1 Rue Héger-Bordet, 1000 Brussels, Belgium. e-mail: email@example.com © 2014 Lippincott Williams & Wilkins, Inc.